Dianthus with Spectral Shift technology is a plate-based affinity screening platform that handles the throughput needed for hit identification and lead validation during PROTAC development. Additionally, it excels in the characterization of ternary complexes and the hook effect with flexible and in-solution affinity measurements for results you can trust.
Ready to tackle your challenging affinity screening?
Discover tools you can use
See more related content
37:25Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
NanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods
56:52Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com
59:35Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...